NCT04926324终止1 期
A Phase 1b/2 Trial of Preoperative Niraparib, Dostarlimab, and Hypofractionated Radiotherapy for the Treatment of Locally-advanced Rectal Cancers.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Determination of the clinical complete response rate
研究概览
简要总结
This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures.
详细描述
Standard of care therapy for resectable locally advanced rectal cancer includes pelvic radiation (short or long course), chemotherapy, and (if indicated) surgery.
In this study, participants will:
- Take niraparib by mouth once daily for up to 12 weeks.
- Receive radiation therapy once daily for five days (Monday through Friday).
- Receive intravenous (IV) dostarlimab once every three weeks for up to 12 weeks.
- Provide feedback about how they feel and their quality of life. This is done through short surveys as well as discussing with the study team.
- Undergo a sigmoidoscopy (i.e. scope of the tumor) and biopsy about halfway through treatment
- Provide tumor tissue and blood samples for analysis
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand and willingness to provide independent informed consent; legally authorized representative consent and/or power-of-attorney is not allowed.
- •Age at least 18 years at the time of study drug administration
- •Resectable locally advanced rectal cancer (i.e., T3 to T4 or T1-T4 with N1-2 M0).
- •Recommended to receive total neoadjuvant therapy consisting of preoperative radiation therapy followed by systemic FOLFOX chemotherapy
- •Adequate performance status (ECOG of 0 or 1; or KPS of >70).
- •Agree to adhere to lifestyle considerations throughout study duration
- •Agree to not donate blood during the study or for 90 days after the last dose of study treatment.
排除标准
- •Absolute neutrophil count < 1,500 cells /µL
- •Platelets < 100,000 cells/µL
- •Hemoglobin <9 g/dL
- •Serum creatinine > 1.5 x upper limit of normal (ULN) or calculated creatinine clearance 60mL/min using the Cockcroft-Gault equation
- •Total bilirubin > 1.5 x ULN (>2.0 x ULN in patients with known Gilberts syndrome) or direct bilirubin > 1 x ULN
- •Aspartate aminotransferase and alanine aminotransferase > 2.5 x ULN
- •International normalized ratio (INR) or prothrombin time (PT) >1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants.
- •Activated partial thromboplastin time (aPTT) >1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- •Uncontrolled arterial hypertension, i.e. systolic BP > 140 mmHg, diastolic BP > 90 mmHg.
- •Platelet transfusion ≤ 4 weeks prior to initiating protocol therapy.
- •Presence of any M1 metastatic lesions.
- •Prior pelvic radiotherapy
- •Indication for total neoadjuvant therapy or alternative radiation regimen
- •Recommended to receive a chemotherapy regimen other than FOLFOX chemotherapy. CapeOX (oral xeloda plus oxaliplatin) is an acceptable alternative as it contains the core fluoropyrimidine + oxaliplatin backbone.
- •Indication for alternative radiation dose or fractionation regimen.
- •Active Crohn's disease or another inflammatory bowel disease
- •Any T or N stage disease that is deemed unresectable by colorectal surgery without neoadjuvant therapy
- •Prior anti-PD-L1 therapy, PARPi therapy, or known germline BRCA-1/2 mutation as patients with germline BRCA-1/2 mutations have an increased risk of severe normal tissue injury to combination radiation and PARP inhibition.
- •Received a live vaccine within 14 days of initiating protocol therapy.
- •Received colony stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) within 4 weeks prior to Day 1 of protocol therapy.
- •Major surgery within 3 weeks prior to Day 1 of protocol therapy (participant must recover from any surgical effects).
- •Investigational therapy ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior to Day 1 of protocol therapy.
- •Known hypersensitivity to niraparib and dostarlimab components or excipients.
- •Known grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment.
- •Known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
- •Diagnosis, detection, or treatment of another type of cancer ≤ 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated).
- •Known history of ≥ grade 3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities.
- •Diagnosis of immunodeficiency or has received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy.
- •Patients with known HIV who have documented detectable viral load or patients with a documented undetectable viral load and a CD 4 count < 350 cells within 6 months of study treatment day
- •Known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected).
- •Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •History of interstitial lung disease.
- •Active or uncontrolled infection necessitating hospitalization or treatment delay.
- •Known serious, uncontrolled medical disorder or nonmalignant systemic disease that preclude eligibility to undergo low anterior resection (LAR). Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, or any psychiatric disorder that prohibits obtaining informed consent
- •Pregnancy. Participant must have a negative serum pregnancy test within 72 hours prior to taking study treatment if of childbearing potential and agrees use a highly effective method of contraception from screening through 180 days after the last dose of niraparib and after the last dose of dostarlimab, or is of nonchildbearing potential. Nonchildbearing potential is defined as follows (by other than medical reasons):
- •≥ 60 years of age
- •Post-hysterectomy. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound.
- •Actively breastfeeding. Participant must agree to not breastfeed during the study or for 8 weeks after the last dose of study treatment.
- •Declines to use a highly effective method of contraception (see Section 5.2.1 for a list of acceptable birth control methods). Eligible patients must agree to highly effective methods of contraception starting with the first dose of study treatment through 180 days after the last dose of niraparib and dostarlimab.
研究组 & 干预措施
Cohort 1 (starting)
Experimental
niraparib, 100 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
干预措施: Short course radiation (Radiation)
Cohort 2
Experimental
niraparib, 200 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
干预措施: Short course radiation (Radiation)
Cohort 1 (starting)
Experimental
niraparib, 100 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
干预措施: Niraparib (Drug)
Cohort 1 (starting)
Experimental
niraparib, 100 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
干预措施: Dostarlimab (Drug)
Cohort 2
Experimental
niraparib, 200 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
干预措施: Niraparib (Drug)
Cohort 2
Experimental
niraparib, 200 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
干预措施: Dostarlimab (Drug)
结局指标
主要结局
Determination of the clinical complete response rate
时间窗: 8
Clinical evaluation of the tumor by both flexible sigmoidoscopy and pelvic MRI
Determination of recommended phase 2 niraparib dose
时间窗: From treatment day 1 for up to 16 weeks.
The recommended dose will be determined by incidence of dose limiting toxicities.
次要结局
- Determine ostomy free survival(From treatment day 1 up to 20 years post-treatment.)
- Determine objective response rate(3 months post-radiation)
- Determination of the pathologic complete response(At surgery; up to 1 year post-treatment)
- Determine overall survival (OS)(Time (measured in days) until death from any cause, up to 20 years post-treatment.)
- Determine progression free survival (PFS)(From treatment day 1 to disease progression, up to 15 years post-treatment)
- Determine metastasis free survival(From treatment day 1 to disease progression or death, up to 20 years post-treatment.)
- Determine local recurrence free survival(From treatment day 1 to disease progression or death, up to 20 years post-treatment.)
- Determination of the organ preservation rate(From treatment day 1 up to 15 years post-treatment)
研究者
Kellie Bodeker, PhD
Associate Director of Theranostics Research
University of Iowa
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerTriple Negative Breast CancerNeoplasmsAdvanced Breast CancerStage IV Breast CancerFallopian Tube CancerPeritoneal CancerBreast CancerOvarian CancerMetastatic Breast CancerNCT02657889Tesaro, Inc.122
进行中（未招募）
2 期
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerProstatic Neoplasms, Castration-ResistantNCT03431350Janssen Research & Development, LLC136
进行中（未招募）
1 期
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian CancerAdvanced Solid TumorOvarian CancerNCT04502602Virginia Commonwealth University18
招募中
2 期
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian CancerStage III Ovarian CancerStage IV Ovarian CancerHigh Grade Ovarian Serous AdenocarcinomaOvarian CancerNCT05961124Sunnybrook Health Sciences Centre40
招募中
2 期
Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaPenile CarcinomaNCT05526989H. Lee Moffitt Cancer Center and Research Institute25